Background: The tcdA-negative variant (A -B
B
+ C. difficile infections (CDI) are not clearly documented. The objective of this study was to investigate these characteristics. Methods: From September 2008 through January 2010, the clinical characteristics, medication history and treatment outcomes of CDI patients were recorded prospectively. Toxin characterization and antibiotic susceptibility tests were performed on stool isolates of C. difficile. 
Conclusions:
The clinical course of A -B + CDI is not different from that of A + B + CDI. Clindamycin use is a significant risk factor for the acquisition of tcdA-negative variant strains.
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Background
Clostridium difficile infection (CDI) is a major cause of healthcare-associated infections worldwide. While the hypervirulent ribotype 027 strain with binary toxin has led to outbreaks only in North America and Europe [1, 2] , toxin A-negative (A -B + ) C. difficile infections have been reported worldwide [3] [4] [5] . The A -B + strain infections occur in an epidemic or sporadic form worldwide, while A -B + CDI is more frequent in East Asian countries [4, [6] [7] [8] [9] .
Initially toxin A was considered to be the most important factor responsible for diarrheal disease [5] ; however, several reports have documented that A -B + strains can lead to similar symptoms, from mild diarrhea to severe pseudomembranous colitis [10, 11] 
Definitions
Diarrhea was defined as unformed stools more than 3 times per day on consecutive days, or 6 times within 36 h. CDI was diagnosed when patients had diarrhea and the C. difficile stool isolates contained toxin genes detected by multiplex PCR [12] . We diagnosed HA-CDI when CDI developed at least 72 h after hospitalization, or within 2 months of the last discharge if the patient did spend time in a healthcare facility [13] .
Clinical cure was defined as resolution of diarrhea within the treatment period, and clinical failure as the need for treatment change to resolve the diarrhea. Resolution of diarrhea required conversion to two or fewer semi-formed or formed stools per day [14] . Recurrence was defined as growth of toxinogenic C. difficile, a positive A&B toxin assay (VIDAS ® C. difficile Toxins A & B; BioMerieux SA, Marcy l'Etoile, France), or a pseudomembrane on endoscopy, with resurgence of symptoms after cessation of treatment at least 10 days after the first episode [15] . Global cure was defined as clinical cure without recurrence.
Collection of data
The demographic and clinical data collected in the study were age, sex, length of hospital stay, medication history within the past 2 months, and underlying diseases including Charlson scores. Installation of a catheter, the use and dosage of antibiotics, probiotics, proton pump inhibitors, H2 blockers, steroids, chemotherapy, and surgical procedure within the past 2 months, were investigated as potential risk factors for CDI [16] . Past medication history was obtained from medical records. The amount of antibiotics administered was expressed as the number of defined daily doses (DDD), which means the total amount of antibiotic divided by the DDD [17] .
Vital signs, stool character, stool frequency, and abdominal pain and tenderness were monitored within 24 h after inclusion. Laboratory tests such as white blood cell (WBC) count, albumin and C-reactive protein (CRP) levels were performed within 24 h of enrollment. Age >60 years, temperature >38.3°C, albumin level <2.5 mg/dL, and WBC count >15,000 cells/mm 3 received 1 point each, and the scores were summed for each patient. Scores above 2 were defined as severe CDI [18, 19] .
Microbiologic studies
Stool specimens were grown anaerobically on C. difficileselective cycloserine-cefoxitin-taurocholate agar (CCFA-TA, Oxoid Ltd., Cambridge, UK), supplemented with 7% horse blood, after alcohol shock treatment [20] . Colonies of C. difficile were identified with API ® Rapid ID 32A (BioMerieux SA, Marcy l'Etoile, France). ATCC 43598 and PCR-ribotype 027 (BI/NAP1/027) were used as internal controls.
Template DNA from stool isolates was used in multiplex PCR to investigate the presence of toxin genes, as described elsewhere, with minor modifications [12] . After the strains producing binary toxin were excluded by multiplex PCR, toxin typing was performed [21] .
Minimum inhibitory concentrations (MICs) of clindamycin and moxifloxacin were measured on supplemented Brucella agar by the E-test (AB-BIOdisc, Solna, Sweden), as recommended by the Clinical and Laboratory Standards Institute (CLSI) [22] . C. difficile ATCC 700057 was used as quality control strain for susceptibility testing.
PCR was performed on template DNA to detect the ermB gene [23] . A PCR product of 688 base pairs on electrophoresis was considered a positive result.
Statistical methods

SPSS version 18
.0 for Windows (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Categorical variables were analysed using Pearson's chi-square test or Fisher's exact test. Continuous variables were analysed using an independent t-test or the Mann-Whitney Utest. Variables with p-values <0.1 on univariate analysis were included in the multivariate analysis. A p-value <0.05 in a two-tailed test of significance was considered statistically significant.
Results
During the study period, 138 C. difficile isolates were obtained from HA-CDI patients; 11 isolates (8.0%) were confirmed by multiplex PCR to have binary toxin genes, 22 ( (Table 1 ). There were no differences in age, sex, length of hospital stay, history of recent surgery or Charlson score between the two groups; however, more cases of chronic obstructive pulmonary disease (COPD) as an underlying disease were identified in the A -B + group (p = 0.049). No differences were found between the two groups with regard to factors associated with the CDI severity score. Using a definition of severe CDI adapted from Zar et al. [18, 19] + strains has increased from 11% to 45% [25] since there was an outbreak. By contrast, Japan has reported a high prevalence of A -B + strains; the peak incidence was 39% in 2000 [10] , and the incidence decreased to 12.7% in 2005-2008 [8] . A report from Shanghai revealed that A -B + strains were responsible for a third of all CDI cases [4] . In Korea, the frequency of A -B + strains was reported to be 4.9% in 1998 [26] , and it then increased to 50.9% in 2004-2005 [7, 11] . In our study, the frequency of A The role of toxin A and toxin B in the pathogenecity of CDI has been debated. Although early studies suggested that toxigenic strains of C. difficile always produce both toxin A and toxin B [5] , one study showed that toxin B is the key virulence factor [27] . However, a recent study figured out that C. difficile producing either one or both toxins showed cytotoxic activity in vitro that translated directly into virulence in vivo [28] . Several studies of the clinical characteristics of A -B + CDI [8, [29] [30] [31] have shown that A -B + strains cause a wide spectrum of diseases from asymptomatic colonization to life-threatening colitis [31] , and that there is no significant difference between the clinical manifestations and outcomes of CDI caused by [11] . Furthermore, severe CDI caused by PCR ribotype 017 was responsible for 5% of cases in Germany, and all these cases had lethal outcomes [30] . In another report, the mortality during a PCR ribotype 017 CDI outbreak attributable to that ribotype was similar to that attributable to PCR ribotype 027 (7.0% vs. 6.5%), and higher than that attributable to other types (7.0% vs. 1.6%) [32] . Conversely, in our study there was no significant difference in the clinical characteristics, the laboratory findings or the incidence of pseudomembranous colitis between the study groups, and there were no deaths attribut- [31] . In this study, the percentage of ermB-positive strains was 53.7% among all C. difficile isolates and 81.0% among the A -B + isolates. Among the A -B + strains, 4 of the 21 isolates were ermB-negative, and all of these were highly resistant to clindamycin. Clindamycin resistance in these strains could also be induced by other mechanisms such as other erm genes, efflux mechanisms, or nucleotide substitutions in other genes [34] . Further study of these resistance mechanisms would be desirable.
In previous studies, moxifloxacin resistance was closely associated with clindamycin resistance (95% CI 68-97%) [34, 35] . It was reported that, of isolates resistant to fluoroquinolones, 98% were resistant to either erythromycin or clindamycin, although fluoroquinolone resistance in the absence of MLS B resistance was rare [35] . Similarly, in our study, resistance to moxifloxacin was highly correlated with clindamycin resistance (p < 0.0001). An efflux pump may be responsible for the co-resistance to the MLS B drugs and fluoroquinolone. 
Conclusions
